Definium Ebitda from 2010 to 2026
| DFTX Stock | 16.25 0.78 4.58% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -95.3 M | Current Value -100 M | Quarterly Volatility 8.3 M |
Check Definium Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Definium Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 11.2 M or Depreciation And Amortization of 450.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.79. Definium financial statements analysis is a perfect complement when working with Definium Therapeutics Valuation or Volatility modules.
Definium | Ebitda | Build AI portfolio with Definium Stock |
The evolution of Ebitda for Definium Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Definium Therapeutics compares to historical norms and industry peers.
Latest Definium Therapeutics' Ebitda Growth Pattern
Below is the plot of the Ebitda of Definium Therapeutics over the last few years. It is Definium Therapeutics' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Definium Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Ebitda | 10 Years Trend |
|
Ebitda |
| Timeline |
Definium Ebitda Regression Statistics
| Arithmetic Mean | (91,280,841) | |
| Coefficient Of Variation | (9.08) | |
| Mean Deviation | 3,369,875 | |
| Median | (91,238,000) | |
| Standard Deviation | 8,286,389 | |
| Sample Variance | 68.7T | |
| Range | 42.7M | |
| R-Value | (0.12) | |
| Mean Square Error | 72.2T | |
| R-Squared | 0.01 | |
| Significance | 0.64 | |
| Slope | (198,217) | |
| Total Sum of Squares | 1098.6T |
Definium Ebitda History
About Definium Therapeutics Financial Statements
Definium Therapeutics investors use historical fundamental indicators, such as Definium Therapeutics' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Definium Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBITDA | -95.3 M | -100 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Definium Stock Analysis
When running Definium Therapeutics' price analysis, check to measure Definium Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Definium Therapeutics is operating at the current time. Most of Definium Therapeutics' value examination focuses on studying past and present price action to predict the probability of Definium Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Definium Therapeutics' price. Additionally, you may evaluate how the addition of Definium Therapeutics to your portfolios can decrease your overall portfolio volatility.